|
|
実績・論文など
[原著(英文)]
1. Kamimura, H., Omi, Y., Shiobara, Y., Tamaki, N. and Katogi, Y.: Simultaneous determination of griseofulvin and 6-desmethylgriseofulvin in plasma by electron-capture gas chromatography. Journal of Chromatography. A.. 163(3):271-9, 1979
2. Kamimura, H., Sasaki, H. and Kawamura, S.: Determination of the alpha,beta-adrenoceptor blocker YM-09538 in plasma by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography. A.. 225(1):115-21, 1981
3. Kamimura, H., Sasaki, H., Higuchi, S. and Shiobara, Y.: Quantitative determination of the beta-adrenoceptor stimulant formoterol in urine by gas chromatography mass spectrometry. Journal of Chromatography. A.. 229(2):337-45, 1982
4. Aoyagi, N., Ogata, H., Kaniwa, N., Koibuchi, M., Shibazaki, T., Ejima, A., Tamaki, N., Kamimura, H., Katougi, Y. and Omi, Y.: Bioavailability of griseofulvin from tablets in beagle dogs and correlation with dissolution rate and bioavailability in humans. Journal of Pharmaceutical Sciences. 71(10):1169-72, 1982
5. Sasaki, H., Kamimura, H., Shiobara, Y., Esumi, Y., Takaichi, M. and Yokoshima, T.: Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs. Xenobiotica. 12(12):803-12, 1982
6. Kamimura H., Sasaki, H., Kawamura, S., Shimizu, M., Matsumoto, H. and Kobayashi, Y.: Determination of the alpha, beta-adrenoceptor blocker YM-09538 in urine by gas chromatography with a nitrogen-sensitive detector. Journal of Chromatography. A.. 275(1):81-7, 1983
7. Kamimura, H., Sasaki, H. and Kawamura, S.: Pharmacokinetics of amosulalol, an alpha, beta-adrenoceptor blocker, in rats, dogs and monkeys. Xenobiotica. 14(8):613-20, 1984
8. Sasaki, H., Kamimura, H., Kaniwa, H., Kawamura, S., Takaichi, M., and Yokoshima, T.: Disposition and metabolism of amosulalol hydrochloride, a new combined alpha- and beta-adrenoceptor blocking agent, in rats, dogs and monkeys. Xenobiotica. 14(8):621-31, 1984
9. Kamimura, H., Sasaki, H., Yokoi, K. and Kawamura, S.: Determination of indeloxazine in plasma by liquid chromatography and gas chromatography-mass spectrometry. Journal of Pharmaceutical Sciences. 74(5):559-61, 1985
10. Kamimura, H., Sasaki, H. and Kawamura, S.: Metabolism of amosulalol hydrochloride in man: quantitative comparison with laboratory animals. Xenobiotica. 15(5):413-20, 1985
11. Kamimura, H., Enjoji, Y., Sasaki, H., Kawai, R., Kaniwa, H., Niigata, K. and Kageyama, S.: Disposition and metabolism of indeloxazine hydrochloride, a cerebral activator, in rats. Xenobiotica. 17(6):645-58, 1987
12. Kamimura, H., Kawai, R. and Kudo, H.: Metabolic fate of indeloxazine hydrochloride: alpha-glucoside formation in rats. Xenobiotica. 18(2):141-9, 1988
13. Kamimura, H., Ogata, H. and Takahara, H.: Alpha-glucoside formation of xenobiotics by rat liver alpha-glucosidases. Drug Metabolism & Disposition. 20(2):309-15, 1992
14. Koiso, K., Akaza, H., Kikuchi, K., Aoyagi, K., Ohba, S., Miyazaki, M., Ito, M., Sueyoshi, T., Matsushima, H., Kamimura, H., Watanabe, T. and Higuchi, S.: Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein. Journal of Clinical Pharmacology. 36(11):1029-38, 1996
15. Matsushima, H., Takanuki, KI., Kamimura, H., Watanabe, T. and Higuchi, S.: Highly sensitive method for the determination of tamsulosin hydrochloride in human plasma dialysate, plasma and urine by high-performance liquid chromatography-electrospray tandem mass spectrometry. Journal of Chromatography. B, Biomedical Sciences & Applications. 695(2):317-27, 1997
16. Matsushima, H., Kamimura, H., Soeishi, Y., Watanabe, T., Higuchi, S. and Tsunoo, M.: Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metabolism & Disposition. 26(3):240-5, 1998
17. Kamimura, H., Oishi, S., Matsushima, H., Watanabe, T., Higuchi, S., Hall, M., Wood, SG. and Chasseaud, LF.: Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 28(10):909-22, 1998
18. Matsushima, H., Kamimura, H., Soeishi, Y., Watanabe, T., Higuchi, S. and Miyazaki, M.: Plasma protein binding of tamsulosin hydrochloride in renal disease: role of alpha1-acid glycoprotein and possibility of binding interactions. European Journal of Clinical Pharmacology. 55(6):437-43, 1999
19. Oikawa, K., Kamimura, H., Watanabe, T., Miyamoto, I. and Higuchi S.: Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys. Thrombosis Research. 101(6):493-500, 2001
20. Miyazawa, Y., Starkey, LP., Forrest, A., Schentag, JJ., Kamimura, H., Swarz, H. and Ito, Y.: Effects of the concomitant administration of tamsulosin (0.8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin) in normal healthy subjects: a placebo-controlled evaluation. Journal of Clinical Pharmacy & Therapeutics. 27(1):13-9, 2002
21. Miyazawa, Y., Starkey, LP., Forrest, A., Schentag, JJ., Kamimura, H., Swarz, H. and Ito, Y.: Effects of the concomitant administration of tamsulosin (0.8 mg/day) on the pharmacokinetic and safety profile of theophylline (5 mg/kg): a placebo-controlled evaluation. Journal of International Medical Research. 30(1):34-43, 2002
22. Mano, Y., Aoki, T., Kikuchi, Y., Soeishi, Y., Usui, T. and Kamimura, H.: LC determination of YM466, a new factor Xa inhibitor, in rat and dog plasma. Journal of Pharmaceutical & Biomedical Analysis. 29(4):631-8, 2002
23. Mano, Y., Higuchi, S., and Kamimura, H.: Investigation of the high partition of YM992, a novel antidepressant, in rat brain - in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopharmaceutics & Drug Disposition. 23(9):351-60, 2002
24. Mano, Y., Usui, T. and Kamimura, H.: Pharmacokinetics of YM466, a new factor Xa inhibitor, in rats and dogs. European Journal of Drug Metabolism & Pharmacokinetics. 29(1):7-13, 2004
25. Mano, Y., Sonoda, T., Nakamura, E., Usui, T. and Kamimura, H.: Absorption, distribution, metabolism and excretion of YM466, a novel factor Xa inhibitor, in rats. Biopharmaceutics & Drug Disposition. 25(6):253-60, 2004
26. Hashimoto, T., Narikawa, S., Huang, XL., Minematsu, T., Usui, T., Kamimura, H. and Endou H.: Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters. Drug Metabolism & Disposition. 32(10):1096-102, 2004
27. Mano, Y., Usui, T. and Kamimura, H.: Effects of beta-estradiol and propofol on the 4-methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9. Biopharmaceutics & Drug Disposition. 25(8):339-44, 2004
28. Sohda, K., Minematsu, T., Hashimoto, T., Suzumura, K., Funatsu, M., Suzuki, K., Imai, H., Usui, T. and Kamimura, H.: Application of LC-NMR for characterization of rat urinary metabolites of zonampanel monohydrate (YM872). Chemical & Pharmaceutical Bulletin. 52(11):1322-5, 2004
29. Tenmizu, D., Fukunaga, Y., Noguchi, K. and Kamimura, H.: Simultaneous determination of YM-64227, a phosphodiesterase type 4 inhibitor, and its five metabolites in dog plasma by high-performance liquid chromatography with fluorescence detection. Biomedical Chromatography. 18(9):667-72, 2004
30. Mano, Y., Usui, T., and Kamimura, H.: A liquid chromatographic-tandem mass spectrometric method for the determination of YM466, a novel Factor Xa inhibitor, in rat plasma. Journal of Pharmaceutical & Biomedical Analysis. 36(4):883-7, 2004
31. Tenmizu, D., Endo, Y., Noguchi, K. and Kamimura, H.: Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion. Xenobiotica. 34(9):835-46, 2004
32. Mano, Y., Usui, T. and Kamimura H.: In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3beta- glucuronidation in human liver microsomes. Biopharmaceutics & Drug Disposition. 26(1):35-9, 2005
33. Minematsu, T., Sohda, KY., Hashimoto, T., Imai, H., Usui, T. and Kamimura H.: Identification of metabolites of [14C]zonampanel, an a-amino-3-hydroxy-5-methylisoxazole- 4-propionate receptor antagonist, following intravenous infusion in healthy volunteers. Xenobiotica. 35(4):359-71, 2005
34. Mano, Y., Usui, T. and Kamimura, H.: In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP- glucuronosyltransferase 1A9--potent inhibition by niflumic acid. Biopharmaceutics & Drug Disposition. 27(1):1-6, 2006
35. Mano, Y., Usui, T. and Kamimura, H.: Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats. European Journal of Drug Metabolism & Pharmacokinetics. 31(2):117-21, 2006
36. Tenmizu, D., Noguchi, K., Kamimura, H., Ohtani, H. and Sawada, Y.: The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl- 7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor. Drug Metabolism & Disposition. 34(5):800-6, 2006
37. Mano, Y., Usui, T. and Kamimura, H.: Identification of human UDP-glucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver. Pharmaceutical Research. 23(7):1502-8, 2006
38. Mano, Y., Usui, T. and Kamimura, H.: In vitro drug interaction between diflunisal and indomethacin via glucuronidation in humans. Biopharmaceutics & Drug Disposition. 27(6):267-73, 2006
39. Tenmizu, D., Noguchi, K. and Kamimura, H.: Elucidation of the effects of the CYP1A2 deficiency polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7- methylpyrido[2,3- d]pyrimidine-2-(1h)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs. Drug Metabolism & Disposition. 34(11):1811-6, 2006
40. Kato, K., Noguchi, K., Aoki, T., Soeishi, Y. and Kamimura, H.: Simultaneous determination of YM928, a novel noncompetitive AMPA receptor antagonist, and its demethylated metabolite in rat, dog and monkey plasma by high-performance liquid chromatography with ultraviolet detection. Biomedical Chromatography. 20(12):1328-35, 2006
41. Mano, Y., Usui, T. and Kamimura H.: Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharmaceutics & Drug Disposition. 28(1):13-8, 2007
42. Mano, Y., Usui, T. and Kamimura, H.: Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes. Drug Metabolism & Disposition. 35(4):602-6, 2007
43. Mano, Y., Usui, T. and Kamimura, H.: Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. European Journal of Clinical Pharmacology. 63(3):289-96, 2007
44. Mano, Y., Usui, T. and Kamimura, H.: Predominant contribution of UDP- glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metabolism & Disposition. 35(7):1182-7, 2007
45. Umehara, KI., Iwatsubo, T., Noguchi, K. and Kamimura, H.: Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates. Xenobiotica. 37(6):618-34, 2007
46. Suzuki, K. and Kamimura H.: Pharmacokinetics and metabolism of an alpha,beta-blocker, amosulalol hydrochloride, in mice: biliary excretion of carbamoyl glucuronide. Biological & Pharmaceutical Bulletin. 30(8):1580-5, 2007
47. Kamiyama, Y., Matsubara, T., Yoshinari, K., Nagata, K., Kamimura, H. and Yamazoe Y.: Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metabolism & Pharmacokinetics. 22(4):287-98, 2007
48. Umehara, KI., Iwatsubo, T., Noguchi, K. and Kamimura, H.: Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica. 37(8):818-31, 2007
49. Yanagihara, T., Aoki, T., Soeishi, Y., Iwatsubo, T. and Kamimura, H.: Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical & Life Sciences. 859(2):241-5, 2007
50. Mano, Y., Usui, T. and Kamimura, H.: Substrate-dependent modulation of UDP- glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic & Clinical Pharmacology & Toxicology. 101(3):211-4, 2007
51. Mano, Y., Usui, T. and Kamimura H.: The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metabolism & Disposition. 35(11):2040-4, 2007
52. Mano, Y., Usui, T. and Kamimura H.: Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans. J Pharm Sci. 97(7):2805-10. 2008
53. Umehara, KI., Iwatsubo, T., Noguchi, K. and Kamimura, H.: Functional involvement of the organic cation transporter 2 (rOct2) in the renal uptake of organic cations in rats. Journal of International Medical Research. 36(1):123-36, 2008
54. Umehara, KI., Seya, K., Sonoda, T., Nakamura, E., Noguchi, K., Usui, T. and Kamimura H.: Comparative evaluation of absorption, distribution, and excretion of YM758, a novel If channel inhibitor, between albino and non-albino rats. Xenobiotica. 38(5): 527-39, 2008
55. Umehara, KI., Iwai, M., Adachi, Y., Iwatsubo, T., Usui, T. and Kamimura, H.: Hepatic uptake and excretion of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline- 2-carbonyl)-piperidino]ethyl}-4-fluorobenzamide (YM758), a novel if channel inhibitor, in rats and humans. Drug Metabolism and Disposision. 36(6): 1030-38, 2008
56. Noguchi, K., Miyashita, A., Hashimoto, T., Aoki, T., Soeishi, Y. and Kamimura, H.: Solid-phase extraction followed by purification with tri-n-butylphosphate as a simple and useful rat plasma clean-up method for HPLC-UV determination of zonampanel monohydrate (YM872), a highly water-soluble α-amino-3-hydroxy-5-methyl- isoxazole-4-propionic acid receptor antagonist. Journal of Liquid Chromatography & Related Technologies. 31(7):1072-80, 2008
57. Fujita, E., Teramura, Y., Mitsugi, K., Ninomiya, SI., Iwatsubo, T., Kawamura, A. and Kamimura H.: Absorption, distribution, and excretion of 14C-labeled tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. Journal of Ocular Pharmacology and Therapeutics. 24(3):333-43, 2008
58. Fujita, E., Teramura, Y., Shiraga, T., Yoshioka, SI., Iwatsubo, T., Kawamura, A. and Kamimura H.: Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. Journal of Ocular Pharmacology and Therapeutics. 24(3):309-19, 2008
59. Minematsu, T., Felder, L., Oppeneer, T., Sakazume, M., Oikawa, K., Hashimoto, T., Usui, T. and Kamimura H.: Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma. Biomedical Chromatography 22(7): 763-69, 2008
60. Minematsu, T., Hashimoto, T., Aoki, T., Usui, T. and Kamimura, H.: Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3- hydroxy-5-methylisoxazole- 4-propionate receptor antagonist, in rats. Drug Metabolism and Disposition 36:1496-504, 2008
61. Minematsu, T., Hashimoto, T., Usui, T. and Kamimura, H.: Characterization of renal tubular apical efflux of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole- 4-propionate receptor antagonist, in humans. Xenobiotica. 38(9):1191-1202. 2008
62. Umehara, KI., Iwatsubo, T., Noguchi, K., Usui, T. and Kamimura, H.: Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions. Xenobiotica. 38(9):1203-18. 2008
63. Umehara, KI., Nakamata, T., Suzuki, K., Noguchi, K., Usui, T. and Kamimura, H.: Pharmacokinetics of YM758, a novel If channel inhibitor in rats, dogs and humans. Eur J Drug Metab Pharmacokinet. 33(2):117-27. 2008
64. Umehara, KI., Seya, K., Iwatsubo, T., Noguchi, K., Usui, T. and Kamimura, H.: Tissue distribution of YM758, a novel If channel inhibitor, in pregnant and lactating rats. Xenobiotica. 38(10):1274-88. 2008
65. Umehara, KI., Susaki, Y., Van Teylingen, RH., Neat, JN., Ndikum-Moffor, F., Noguchi, K., Usui, T., Parkinson, A. and Kamimura, H.: Evaluation of the inhibitory and induction potential of YM758, a novel If channel inhibitor, for human P450-mediated metabolism. Eur J Drug Metab Pharmacokinet. 33(4):211-23. 2008
66. Minematsu, T., Iwai, M., Sugimoto, K., Shirai, N., Nakahara, T., Usui, T. and Kamimura, H.: Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2- ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab Dispos. 37(3):619-28. 2009
67. Umehara, K., Wada, K., Noguchi, K., Iwatsubo, T., Usui, T. and Kamimura H.: Relationship between exposure of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline- 2-carbonyl) piperidino]ethyl}-4-fluorobenzamide (YM758), a "funny" if current channel inhibitor, and heart rate reduction in tachycardia-induced beagle dogs. Drug Metab Dispos. 37(7):1427-33. 2009
68. Umehara, KI., Shirai, N., Iwatsubo, T., Noguchi, K., Usui, T. and Kamimura, H.: Identification of human metabolites of YM758, a novel If channel inhibitor, and investigation of the transporter-mediated renal and hepatic excretion of these metabolites. Drug Metab Dispos. in press, 2009
69. Iwai, M., Minematsu, T., Narikawa, S., Usui, T. and Kamimura, H.: Involvement of Human Organic Cation Transporter 1 (OCT1) in the Hepatic Uptake of YM155 Monobromide, 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide, a Novel, Small Molecule Survivin Suppressant. Drug Metab Dispos. in press, 2009
[原著(和文)]
1. 佐々木弘三、神村秀隆、塩原雄一、Formoterol fumarate のラットにおける連続投与時の生体内動態：応用薬理 26(1):47-53, 1983
2. 円城寺四方弘、神村秀隆、佐々木弘三、川井龍太郎、Indeloxazine hydrochloride (YM-08054)のラットにおける吸収、分布、代謝および排泄：応用薬理 30(5):853-865, 1985
3. 神村秀隆，松本久夫、佐々木弘三、川井龍太郎、脳機能改善剤塩酸インデロキサジンのヒトにおける代謝：基礎と臨床19(9):4616-4624, 1985
[総説(英文)]
1. Kamimura H.: Genetic polymorphism of cytochrome P450s in beagles: possible influence of CYP1A2 deficiency on toxicological evaluations. Archives of Toxicology. 80(11): 732-738, 2006
2. Kamimura, H., Nakada, N., Suzuki, K., Mera, A., Souda, K., Murakami, Y., Tanaka, K., Iwatsubo, T., Kawamura, A. and Usui, T.: Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. in preparation
[総説(和文)]
1. 神村秀隆： 実験用ビーグル犬の薬物代謝酵素遺伝子診断は、薬理試験、安全性試験の質を高める？ Drug Metab. Pharmacokinet. 20:12-13, 2005
2. 神村秀隆、天水大介： ビーグル犬におけるシトクロムP450の遺伝的多型 ―安全性評価に及ぼす可能性―. 谷本学校 毒性質問箱 サイエンティスト社 第11号 100-110, 2008
[学会発表(国内学会)]
1. In vitro におけるα-グルコース抱合体代謝物の生成
神村秀隆、松井秀文
第19回薬物代謝と活性シンポジウム、大阪、1988
2. Metabolism of YM155 Monobromide, a Novel Survivin Suppressant: In Vitro Species
Comparison and Identification of Metabolites in Rats
Sohda, K., Suzuki, K., Nakamura, E., Minematsu, T., Hashimoto, T., Kinoyama, I., Imai, H., Usui, T., Kawamura, A., Kamimura, H
第８回 International ISSX meeting, 仙台, 2007
3. Characterization of renal tubular apical efflux of zonampanel, an α-amino-3-hydroxy-5-
methylisoxazole-4-propionate receptor antagonist, in humans
Minematsu, T., Hashimoto T., Usui, T., Kamimura, H
第30回生体膜と薬物の相互作用シンポジウム、 北海道、2008
[学会発表(国際学会)]
1. Identification of P450 Isozymes Involved in Metabolism of theα1-Adrenoceptor Blocker Tamsulosin in Human Liver Microsomes
Kamimura, H., Oishi, S., Matsushima, H., Watanabe, T., Higuchi, S., Hall, M., Wood, SG., Chasseaud, LF
4th International ISSX meeting, Seattle, USA, 1995
2. Isolation and Identification of a Major Metabolite of Micafungin in Dogs and Evaluation of Enzymes Involved in its Formation
Kaneko, H., Shiraga, T., Katashima, M., Kawamura, A., Kagayama, A., Kamimura, H
13th North American ISSX/20th JSSX Meeting, Maui, USA, 2005
3. Carrier-mediated Uptake of YM155, a Novel Survivin Suppressant, into Human Cancer Cells
in Vitro
Minematsu, T., Iwai, M., Nakahara, T., Usui, T., Kamimura, H
9th European ISSX meeting, Manchester, UK, 2006